Device Trial Radar · NCT03032211
Optimal Balance Alfapump® System Feasibility Study
Last checked: Nov 20, 2026Latest source record: Mar 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 31, 2017
Primary completion
Dec 31, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- Sequana Medical N.V.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1\. Summary of Clinical Investigation A summary of the clinical investigation is provided below and includes the primary objective of the study, the safety and feasibility endpoints, the number of subjects to be enrolled, the study duration, the subject follow-up and the inclusion/exclusion criteria. 1. Primary Objective The primary objective of the study is to evaluate the safety and feasibility of the alfapump® System indication for use in the management of fluid in NYHA Class III and ambulatory NYHA Class IV heart failure patients who have an eGFR of \> 15 to \< 60 mL/min/1.73m2. 2. Study Endpoints 1. Primary Safety Endpoint The primary safety endpoint will be an assessment of the occurrence of adverse events (AEs) and serious adverse events (SAEs) related to: 1. Surgical implant of the alfapump® 2. Device malfunctions 3. Dialysate infusion 2. Secondary Safety Endpoints The secondary endpoint will be an assessment of: 1. Time to first hospitalization related to fluid management after the activation of the alfapump® System and initiation of dialysate infusion has occurred 2. Rate of occurrence of re-hospitalizations related to fluid management 3. All-cause mortality 3. Assessment of Feasibility for Fluid Management in Heart Failure Indication The feasibility of the alfapump® System for management of fluid in NYHA Class III and ambulatory NYHA Class IV heart failure patients with renal dysfunction will be assessed by the net fluid balance as measured by the ability of the alfapump® System to move more fluid to the bladder than dialysate instilled.
Conditions
- Heart Failure
Interventions
AlfapumpDevice
Implant Alfapump® System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Q1 2017 and Q3 2017
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Military Hospital - State Health Centre
Budapest, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.